Feb 12 (Reuters) - India's Zydus Lifesciences and its U.S. unit will pay $120 million ‌to Astellas Pharma as part of ‌a deal to settle a patent dispute over the ​Japanese drugmaker's bladder disorder drug Mirabegron, the Indian firm said on Thursday. Zydus and its unit will also pay a pre-paid per‑unit licensing ‌fee on sales ⁠of its generic Mirabegron in the U.S. from the date of the ⁠agreement until September 2027, the company said. The deal will enable the company to continue ​marketing its ​generic ...

Drugmaker Lupin has entered into a Settlement and License Agreement with Astellas Pharma Inc, involving a patent infringement dispute over its product ‘Mirabegron’.“Lupin will pay Astellas $90 million, which includes a Prepaid Option Payment of $75 million, and a Prepaid Per Unit License Fee for each unit of Lupin Product sold from the date of the settlement through September 2027,” the company told the stock exchanges.The product is indicated for treating an overactive bladder with symptoms of urge urinary ...

In a regulatory filing on Tuesday, the company said it and its wholly owned subsidiary, Under the agreement, Lupin will pay Astellas $90 million, which includes a prepaid option payment of $75 million, along with a prepaid per-unit licence fee for each unit of the Lupin product sold from the date of settlement through September 2027. The financial and commercial terms of the settlement remain confidential.The company said the agreement resolves its pending litigation with Astellas and enables it to continu ...

Core Viewpoint - Indian drugmaker Lupin has settled a patent infringement dispute with Japan's Astellas Pharma regarding the bladder disorder drug Mirabegron, enabling Lupin to continue selling the product [1] Company Summary - Lupin has reached a settlement that allows it to maintain its market presence for Mirabegron, a drug used to treat bladder disorders [1] - The resolution of this dispute is significant for Lupin as it secures its ability to sell a key product without legal hindrances [1] Industry Summary - The settlement highlights ongoing patent disputes within the pharmaceutical industry, particularly concerning generic drug manufacturers and brand-name companies [1] - The outcome of such disputes can influence market dynamics and competition in the bladder disorder treatment segment [1]